Variables | Dichotomisation | QF Lesion | QF TL | QF NTL | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
median (IQR) | p | median (IQR) | p | median (IQR) | p | ||||||||
Sex | Male vs. Female | 0.23 (0.14-0.34) | vs | 0.22 (0.13-0.33) | 0.50 | 0.29 (0.20-0.37) | vs | 0.25 (0.17-0.29) | 0.22 | 0.27 (0.19-0.36) | vs | 0.27 (0.22-0.40) | 0.79 |
Age (y) | > 73 vs ≤73 | 0.21 (0.14-0.33) | vs | 0.23 (0.14-0.34) | 0.54 | 0.25 (0.16-0.33) | vs | 0.26(0.20-0.34) | 0.61 | 0.24 (0.19-0.43) | vs | 0.28 (0.24-0.32) | 0.47 |
Previous Liver surgery | Yes vs No | 0.26 (0.15-0.34) | vs | 0.22 (0.14-0.32) | 0.74 | 0.28 (0.18-0.39) | vs | 0.26 (0.17-0.30) | 0.53 | 0.24 (0.20-0.33) | vs | 0.28 (0.19-0.39) | 0.70 |
Previous Bevacizumab | Yes vs No | 0.19 (0.13-0.34) | vs | 0.26 (0.17-0.33) | 0.07 | 0.24 (0.17-0.33) | vs | 0.27 (0.19-0.33) | 0.98 | 0.27 (0.18-0.33) | vs | 0.28 (0.23-0.43) | 0.19 |
Delay predictive / post-treatment dosimetry (d) | > 9 vs ≤9 | 0.26 (0.17-0.38) | vs | 0.19 (0.12-0.30) | 0.003 | 0.28 (0.22-0.37) | vs | 0.22 (0.15-0.27) | 0.03 | 0.33 (0.28-0.41) | vs | 0.22 (0.18-0.28) | 0.004 |
Net administered activity (MBq) | > 1262 vs ≤1262 | 0.20 (0.13-0.34) | vs | 0.24 (0.16-0.33) | 0.49 | 0.25 (0.20-0.35) | vs | 0.26 (0.17-0.33) | 0.64 | 0.26 (0.19-0.35) | vs | 0.28 (0.21-0.41) | 0.50 |
Lesion Volume (ml) | > 5.8 vs ≤5.8 | 0.23 (0.15-0.32) | vs | 0.21 (0.13-0.34) | 0.51 |  |  |  |  | ||||
TL Volume (ml) | > 73.34 vs ≤73.34 |  |  | 0.28 (0.16-0.37) | vs | 0.26 (0.20-0.30) | 0.40 |  |  | ||||
NTL Volume (ml) | > 1354 vs ≤1354 |  |  |  |  | 0.29 (0.21-0.41) | vs | 0.27 (0.20-0.31) | 0.37 | ||||
Type of targeting | Whole liver single injection | 0.17 (0.12-0.28) | Â | Â | 0.02 | 0.20 (0.15-0.28) | Â | Â | 0.65 | 0.23 (0.17-0.33) | 0.42 | ||
Whole Liver injection left and right lobes separately | 0.24 (0.14-0.35) | Â | Â | 0.27 (0.17-0.37) | Â | Â | 0.31 (0.19-0.41) | ||||||
Uni-lobar | 0.26 (0.18-0.33) | Â | Â | 0.27 (0.22-0.33) | Â | Â | 0.28 (0.24-0.38) |